Skip to main content
PMC home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1992 Feb;105(2):453–457. doi: 10.1111/j.1476-5381.1992.tb14274.x

Effects of the P2-purinoceptor antagonist, suramin, on human platelet aggregation induced by adenosine 5'-diphosphate.

S M Hourani 1, D A Hall 1, C J Nieman 1
PMCID: PMC1908649  PMID: 1559134

Abstract

1. The effects of suramin, a trypanocidal drug which has been reported to be a P2-purinoceptor antagonist on smooth muscle, were investigated in human platelets, where adenosine 5'-diphosphate (ADP) induces aggregation by acting on a subtype of purinoceptors which has been called P2T. 2. Suramin (100 microM) had no inhibitory effect on ADP-induced platelet aggregation in plasma, even after 40 min incubation in the presence of bacitracin, a peptidase inhibitor, and did not affect the ability of adenosine 5'-triphosphate (ATP) (40 microM) to inhibit competitively ADP-induced aggregation. This lack of effect of suramin on platelets in plasma is probably due to its extensive binding to plasma proteins. 3. In washed platelets, suramin (50-400 microM) acted as an apparently competitive antagonist, causing parallel shifts to the right of the log concentration-response curve to ADP. No depression of the maximal response to ADP was observed at concentrations of suramin (50-150 microM) for which full log concentration-response curves to ADP could be obtained, but the slope of the Schild plot was around 2, indicating that this antagonism was not simply competitive. The apparent pA2 value for suramin, taken from this Schild plot, was 4.6. 4. Suramin (200-400 microM) also noncompetitively inhibited aggregation induced by U46619 (a thromboxane receptor agonist) or by 5-hydroxytryptamine in the presence of adrenaline (100 microM), and caused a depression of the maximal response to these agonists. This nonspecific effect of suramin may explain the high Schild plot slope obtained against ADP.(ABSTRACT TRUNCATED AT 250 WORDS)

Full text

PDF
455

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. ARUNLAKSHANA O., SCHILD H. O. Some quantitative uses of drug antagonists. Br J Pharmacol Chemother. 1959 Mar;14(1):48–58. doi: 10.1111/j.1476-5381.1959.tb00928.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. BORN G. V. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature. 1962 Jun 9;194:927–929. doi: 10.1038/194927b0. [DOI] [PubMed] [Google Scholar]
  3. Broder S., Yarchoan R., Collins J. M., Lane H. C., Markham P. D., Klecker R. W., Redfield R. R., Mitsuya H., Hoth D. F., Gelmann E. Effects of suramin on HTLV-III/LAV infection presenting as Kaposi's sarcoma or AIDS-related complex: clinical pharmacology and suppression of virus replication in vivo. Lancet. 1985 Sep 21;2(8456):627–630. doi: 10.1016/s0140-6736(85)90002-9. [DOI] [PubMed] [Google Scholar]
  4. Burnstock G., Kennedy C. Is there a basis for distinguishing two types of P2-purinoceptor? Gen Pharmacol. 1985;16(5):433–440. doi: 10.1016/0306-3623(85)90001-1. [DOI] [PubMed] [Google Scholar]
  5. Butler S. J., Kelly E. C., McKenzie F. R., Guild S. B., Wakelam M. J., Milligan G. Differential effects of suramin on the coupling of receptors to individual species of pertussis-toxin-sensitive guanine-nucleotide-binding proteins. Biochem J. 1988 Apr 1;251(1):201–205. doi: 10.1042/bj2510201. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Calcaterra N. B., Vicario L. R., Roveri O. A. Inhibition by suramin of mitochondrial ATP synthesis. Biochem Pharmacol. 1988 Jul 1;37(13):2521–2527. doi: 10.1016/0006-2952(88)90241-9. [DOI] [PubMed] [Google Scholar]
  7. Collins J. M., Klecker R. W., Jr, Yarchoan R., Lane H. C., Fauci A. S., Redfield R. R., Broder S., Myers C. E. Clinical pharmacokinetics of suramin in patients with HTLV-III/LAV infection. J Clin Pharmacol. 1986 Jan;26(1):22–26. doi: 10.1002/j.1552-4604.1986.tb02897.x. [DOI] [PubMed] [Google Scholar]
  8. Colman R. W. Aggregin: a platelet ADP receptor that mediates activation. FASEB J. 1990 Mar;4(5):1425–1435. doi: 10.1096/fasebj.4.5.2407587. [DOI] [PubMed] [Google Scholar]
  9. Colman R. W., Figures W. R., Colman R. F., Morinelli T. A., Niewiarowski S., Mills D. C. Identification of two distinct adenosine diphosphate receptors in human platelets. Trans Assoc Am Physicians. 1980;93:305–316. [PubMed] [Google Scholar]
  10. Cusack N. J., Hourani S. M. Adenosine 5-diphosphate antagonists and human platelets: no evidence that aggregation and inhibition of stimulated adenylate cyclase are mediated by different receptors. Br J Pharmacol. 1982 May;76(1):221–227. doi: 10.1111/j.1476-5381.1982.tb09210.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Cusack N. J., Hourani S. M. Subtypes of P2-purinoceptors. Studies using analogues of ATP. Ann N Y Acad Sci. 1990;603:172–181. doi: 10.1111/j.1749-6632.1990.tb37671.x. [DOI] [PubMed] [Google Scholar]
  12. Den Hertog A., Van den Akker J., Nelemans A. Suramin and the inhibitory junction potential in taenia caeci of the guinea-pig. Eur J Pharmacol. 1989 Dec 7;173(2-3):207–209. doi: 10.1016/0014-2999(89)90522-0. [DOI] [PubMed] [Google Scholar]
  13. Dunn P. M., Blakeley A. G. Suramin: a reversible P2-purinoceptor antagonist in the mouse vas deferens. Br J Pharmacol. 1988 Feb;93(2):243–245. doi: 10.1111/j.1476-5381.1988.tb11427.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Fortes P. A., Ellory J. C., Lew V. L. Suramin: a potent ATPase inhibitor which acts on the inside surface of the sodium pump. Biochim Biophys Acta. 1973 Aug 22;318(2):262–272. doi: 10.1016/0005-2736(73)90119-3. [DOI] [PubMed] [Google Scholar]
  15. Gordon J. L. Extracellular ATP: effects, sources and fate. Biochem J. 1986 Jan 15;233(2):309–319. doi: 10.1042/bj2330309. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Hoiting B., Molleman A., Nelemans A., Den Hertog A. P2-purinoceptor-activated membrane currents and inositol tetrakisphosphate formation are blocked by suramin. Eur J Pharmacol. 1990 May 31;181(1-2):127–131. doi: 10.1016/0014-2999(90)90253-3. [DOI] [PubMed] [Google Scholar]
  17. Hourani S. M., Chown J. A. The effects of some possible inhibitors of ectonucleotidases on the breakdown and pharmacological effects of ATP in the guinea-pig urinary bladder. Gen Pharmacol. 1989;20(4):413–416. doi: 10.1016/0306-3623(89)90188-2. [DOI] [PubMed] [Google Scholar]
  18. Hourani S. M., Cusack N. J. Pharmacological receptors on blood platelets. Pharmacol Rev. 1991 Sep;43(3):243–298. [PubMed] [Google Scholar]
  19. Hoyle C. H., Knight G. E., Burnstock G. Suramin antagonizes responses to P2-purinoceptor agonists and purinergic nerve stimulation in the guinea-pig urinary bladder and taenia coli. Br J Pharmacol. 1990 Mar;99(3):617–621. doi: 10.1111/j.1476-5381.1990.tb12979.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Inoue K., Nakazawa K., Ohara-Imaizumi M., Obama T., Fujimori K., Takanaka A. Selective and competitive antagonism by suramin of ATP-stimulated catecholamine-secretion from PC12 phaeochromocytoma cells. Br J Pharmacol. 1991 Mar;102(3):581–584. doi: 10.1111/j.1476-5381.1991.tb12216.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Leff P., Wood B. E., O'Connor S. E. Suramin is a slowly-equilibrating but competitive antagonist at P2x-receptors in the rabbit isolated ear artery. Br J Pharmacol. 1990 Nov;101(3):645–649. doi: 10.1111/j.1476-5381.1990.tb14134.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Macfarlane D. E., Mills D. C., Srivastava P. C. Binding of 2-azidoadenosine [beta-32P]diphosphate to the receptor on intact human blood platelets which inhibits adenylate cyclase. Biochemistry. 1982 Feb 2;21(3):544–549. doi: 10.1021/bi00532a020. [DOI] [PubMed] [Google Scholar]
  23. Macfarlane D. E., Srivastava P. C., Mills D. C. 2-Methylthioadenosine[beta-32P]diphosphate. An agonist and radioligand for the receptor that inhibits the accumulation of cyclic AMP in intact blood platelets. J Clin Invest. 1983 Mar;71(3):420–428. doi: 10.1172/JCI110786. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Mahoney C. W., Azzi A., Huang K. P. Effects of suramin, an anti-human immunodeficiency virus reverse transcriptase agent, on protein kinase C. Differential activation and inhibition of protein kinase C isozymes. J Biol Chem. 1990 Apr 5;265(10):5424–5428. [PubMed] [Google Scholar]
  25. Moriyama Y., Nelson N. Inhibition of vacuolar H+-ATPases by fusidic acid and suramin. FEBS Lett. 1988 Jul 18;234(2):383–386. doi: 10.1016/0014-5793(88)80121-2. [DOI] [PubMed] [Google Scholar]
  26. Nakazawa K., Fujimori K., Takanaka A., Inoue K. Reversible and selective antagonism by suramin of ATP-activated inward current in PC12 phaeochromocytoma cells. Br J Pharmacol. 1990 Sep;101(1):224–226. doi: 10.1111/j.1476-5381.1990.tb12117.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Offensperger W. B., Walter E., Offensperger S., Zeschnigk C., Blum H. E., Gerok W. Duck hepatitis B virus: DNA polymerase and reverse transcriptase activities of replicative complexes isolated from liver and their inhibition in vitro. Virology. 1988 May;164(1):48–54. doi: 10.1016/0042-6822(88)90618-6. [DOI] [PubMed] [Google Scholar]
  28. Ono K., Nakane H., Fukushima M. Differential inhibition of various deoxyribonucleic and ribonucleic acid polymerases by suramin. Eur J Biochem. 1988 Mar 1;172(2):349–353. doi: 10.1111/j.1432-1033.1988.tb13893.x. [DOI] [PubMed] [Google Scholar]
  29. WILLS E. D., WORMALL A. Studies on suramin; the action of the drug on some enzymes. Biochem J. 1950 Aug;47(2):158–170. doi: 10.1042/bj0470158. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. den Hertog A., Nelemans A., Van den Akker J. The inhibitory action of suramin on the P2-purinoceptor response in smooth muscle cells of guinea-pig taenia caeci. Eur J Pharmacol. 1989 Aug 3;166(3):531–534. doi: 10.1016/0014-2999(89)90370-1. [DOI] [PubMed] [Google Scholar]
  31. von Kügelgen I., Bültmann R., Starke K. Interaction of adenine nucleotides, UTP and suramin in mouse vas deferens: suramin-sensitive and suramin-insensitive components in the contractile effect of ATP. Naunyn Schmiedebergs Arch Pharmacol. 1990 Aug;342(2):198–205. doi: 10.1007/BF00166965. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES